Health

Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

Clean medicine developer Genexa roped in Unilever for its $60m series A round while Krafton led storytelling platform developer Pratilipi's $48m series D.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

The price Eli Lilly is paying for protein drug developer and portfolio company Protomer could potentially top $1bn dependent on milestone payments.

Ionis Pharmaceuticals' stake in the muscular disease treatment developer will be cut in an offering set to raise between $95m and $107m.

All 17 founding health systems have chipped into the health data platform developer’s series A round, which closed with contributions from three new members.

Electric aircraft developer Heart Aerospace raised $35m from investors including Mesa Air and United, while several corporates are set to exit remote access software developer Openpath.

GV has contributed to two rounds for the gene-editing technology developer, which publicly launched yesterday with $315m of funding.

Access Biotechnology helped the small molecule drug developer increase its total funding to over $300m in a round led by BVF Partners.

Tigermed and WuXi Biologics took part in the biopharmaceutical company's series D round, which will accelerate the development of its immuno-oncology drug candidates.

Existing investor Agilent helped the biomedical analysis technology developer close a series C round that pushed its overall funding past $110m.